The World Health Organization has suspended testing the intestinal sickness tranquilize hydroxychloroquine in COVID-19 patients because of security concerns, WHO Director General Tedros Adhanom Ghebreyesus said on Monday.

<span style="color: #ff6600;"><a style="color: #ff6600;" href="https://m.economictimes.com/industry/healthcare/who-pauses-trial-of-hydroxychloroquine-in-covid-19-patients-due-to-safety-concerns/articleshow/75981810.cms">Hydroxycholoroquine has been touted by Donald Trump and others as a potential treatment for the ailment brought about by the novel coronavirus.</a></span> The U.S. President has said he was taking the medication to help forestall disease.

"The official gathering has actualized an impermanent respite of the hydroxychloroquine arm inside the Solidarity preliminary while the wellbeing information is inspected by the information security checking board," Tedros told a web based instructions.

He said different arms of the preliminary - a significant universal activity to hold clinical trial of potential medicines for the infection - were proceeding.

The WHO has recently prescribed against utilizing hydroxychloroquine to treat or forestall coronavirus contaminations, with the exception of as a feature of clinical preliminaries.

Dr. Mike Ryan, leader of the WHO crises program, said the choice to suspend preliminaries of hydroxychloroquine had been removed from "a wealth of alert".